>PROKKA_00001 hypothetical protein
MKKCPVCKTDIKEIEPGVYKCLCGYREIQADEESAVEIRLYNHKTSQVFYKNLTVNEIMQ
IDNILKGIEWE*
>PROKKA_00002 hypothetical protein
MHLKTMKVIEFPKNKMVKDKMKKYKLETAIMMLEVLVDYDFTIVVNPKAAENIFSLPKNK
LIENFIITTDINKAEKLEIKKPCYYQLTGNELT*
>PROKKA_00003 hypothetical protein
METKDYGEIPYTIEIDWINETVWLNNHVAKEKIVVTEKDSKSIENAFKLIKAKRNGLF*
>PROKKA_00004 hypothetical protein
MNEIIVKGMFRMNKTKIKSIIVSIVLVSSLFIVSGCNLLENEYKQLQEHFKGRNAIITTY
DKESKPLDRIEGKSISISLDDKFKEQDEKGETIKKSSVLNITVGNNQIIHVGSSLILQED
GLQDLMKDTLKTTEIINQDKSRPFLRNIVDSYKNITSGKKRVILIRSQDGKPLATFVGDN
VSYFATDIPKSTGILIDGKYLLIYRCDYTIYDMDLIR*
>PROKKA_00005 Modification methylase RsrI
LLEVNNIYLGNCLEIMKKIDDKSIDMVLSDLPFGMTNNKWDKAIPFEPMWQEINRIAKDN
ASIALMAAGVFTSELVVSNKKYYRYSWIWKPKEKSNFLNANRMPLRQHIDIPIFYKNLPV
YNPQKTYGHKPVKKYKQHTTAGANYGKTKIGMEGGGQTDRYPTTIIDIPYNTIKIKDRIH
PTQKPIELYEYLIKTYTNEEGIALDFTAGSCVLAEACINTNRNYICIEKEKKYCNKAKER
IKLHLEKGKQLKII*
>PROKKA_00006 hypothetical protein
MFWFDKENKDVIFMDNRELEDTLCDGRKLIIEPDILGDFRNIPYKDNTFKLVVFDPPHLI
KAGENSWLAKKYGKLNSDWPIDIRQGFNECMRVLDKYGILIFKWNEEQIKIKDILKVIDY
KPLLGNKRAKTHWLVFMKK*
>PROKKA_00007 hypothetical protein
MKKYELVIENPTDAFILDKEKNKIIALCNTKRPDLRFNELKNLIEKANKNTKQLFQLGDI
AYMIDEDYRFFESEVCSIELKNGKYYYNTHDCDFEDKDIGDWVFESEMYRELHLEAMM*
>PROKKA_00008 hypothetical protein
MKVKLIGENKTEVQFSNKKEGNLINQLKFFGAVPTKESSLYTYLQFNGDIQATMDNFGFR
I*
>PROKKA_00009 hypothetical protein
MIKTKLFTGVTVLEAVYDYQDFIKRNQNLEIISVNILKDNFVLLTYKMFKEDIKG*
>PROKKA_00010 hypothetical protein
MISIKRKDEIWNAIYAEPCLLDFNTLNTEELSFAIGIIISAGSRNSFKEDHFNKEQLKFL
KKVFKELLKL*
>PROKKA_00011 hypothetical protein
VKKNQNDISEIEDQVIGRYAKVIITRDIETHYNSTNKIFKNTQI*
>PROKKA_00012 Botulinum neurotoxin type B precursor
MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFN
KSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG
DRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH
FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY
GIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV
DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN
IAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQA
YEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTKNI
YIENYFSINELILDTDLISGIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQY
LYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIIDD
FVIEANKSSTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLI
PVVGAFLLESYIDNKNKIIKTIDNALTKRVEKWIDMYGLIVAQWLSTVNTQFYTIKEGMY
KALNYQAQALEEIIKYKYNIYSEKEKLNINIDFNDINSKLNEGINQAIDNINNFINECSV
SYLMKKMIPLAIEKLLDFDNALKKNLLNYIDENKLYLIGSVEEEKSKVDKFFKTIIPFDL
SMYTNNTILIEMVNKYNSEILNNIILNLRYRDNNLIDSSGYGAKVEVYNGVELNDKNQFK
LTSSANSKIKVTQNQNITFNSMFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNS
GWKISIRGNRIIWTLTDINGKTKSVFFEYSIREDISDYINRWFFVTITNNLDNAKIYING
KLESNIDIRDIREVIVNGEIIFKLDGEIDRTQFIWMKYFSIFNTELSQSNVKEIYKIQSY
SKYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLVKDSSVGEILTRSKYNQNSNYINYRNLY
IGEKFIIRRKSSSQSISDDIVRKEDYIYLDFFNSNREWRVYAYKNFKGQEEKLFLANIYD
SNEFYKTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHNFYESGILFKDYKDYFCIS
KWYLKEVKKKPYSSNLGCNWQFIPKDEGWTE*
>PROKKA_00013 Botulinum neurotoxin type A precursor
MCVEINLGGWLDMNINDNLSINSPVDNKNVVVVRARKTDTVFKAFKVAPNIWVAPERYYG
ESLSIDEEYKVDGGIYDSNFLSQDSEKDKFLQAIITLLKRINSTNAGEKLLSLISTAIPF
PYGYIGGGYYAPNMITFGSAPKSNKKLNSLISSTIPFPYAGYRETNYLSSEDNKSFYASN
IVIFGPGANIVENNTVFYKKEDAENGMGTMTEIWFQPFLTYKYDEFYIDPAIELIKCLIK
SLYFLYGIKPSDDLVIPYRLRSELENIEYSQLNIVDLLVSGGIDPKFINTDPYWFTDNYF
SNAKKVFEDHRNIYETQIEGNNAIGNDIKLRLKQKFRININDIWELNLNYFSKEFSIMMP
DRFNNALKHFYRKQYYKIDYPENYSINGFVNGQINVQLSLSDRNQDIINKPEEIINLLNG
NNVSLMRSNIYGDGLKSTVDDFYSNYKIPYNRAYEYHFNNSNDSSLDNVNIGVIDNIPEI
IDVNPYKENCDKFSPVQKITSTREINTNIPWPINYLQAQNTNNEKFSLSSDFVEVVSSKD
KSLVYSFLSNVMFYLDSIKDNSPIDTDKKYYLWLREIFRNYSFDITATQEINTDCGINKV
VTWFGKALNILNTSDSFVEEFQNLGPISLINKKENLSMPIIEIYGIPNDMLGLPLNDLNE
KLFNIYLKNILYFKKVYFNFLDQWWTEYYSQYFDLICMAKQSILAQEKLIKQIIQNKLQD
LFKADISMDKLNLMNLATEKTFIDLSNESQIAINNINDFLNKSAICVFDTNIYPKFISFM
EQCINSVNSNVTAFIQKCTNITEDEKLQLIKLNTFMNIDFEFFDIQSIKDLITSETDLIK
EEKESDYNLFLFTLQEDNNKVIEDISGKNTLVKYSDSISLVYGVNGDALYLKEPDESVSF
SNKAFENGLTNSFSICFWLRNLGEDIITSKLIENKADNCGWEIYFENNGLVFSIVDCNGN
EENIYLSDVISKNWYYISISIDRLRNQLLIFINDKLIANQSIEQILNIYSSNTISLVNEN
NPIYIEGLSILNRSITSEEVVNNYFSYLNNSYIRDISGERLEYNKTYELYNYVFPENSLY
EVTENNNIYLSIKDTNNLNIQGAKFKLINIDANKQYVQKWDEGVVCLLGDEEKYVDISSE
NNRIQLVNSKDTAKRIIFNNDIFMPNCLTFAYNNKYLSLSLRDRNYNWMICNNNDNIPKA
AHLWALKGI*
>PROKKA_00014 transcriptional regulator BotR, P-21
VVNMNKLFLQIEMLKNDNEEFQEIFKHFEKTINIFTRKYNIYDNYNDILYHLWYTLKKVD
LSNFNTQNDLERYISRTLKRYCLDICNKRKIDKKIIYNSEIADKKLSLIANSYSSYSEFE
FNDLISILPDDQKKIIYMKFVEDIKEIDIAKKLNISRQSVYKNKIMALERLEPILKKLIN
M*
>PROKKA_00015 hypothetical protein
MEHYSVIQNSLNDKIVTISCKADTNLFFYQAAGTDNVILFQQIRDYLERWRLIYDSNKAA
YKIKSMNIHNTNLVLTWNSPTHNISTQQDSNADNQYWLLLKDIGNNSFIIASYKNPNLVL
YADTVAHNLKLSTLNNSNYIKFIIEDYIISDLNNFTCKISPILASNKVVQQVAMTDLNVN
LYTWNYGRNQKWTIRYNEEKAAYQFFNEILSNGVLTWIFSNGNTVRVSSNDQNNDAQYWL
INPVPDNYRRYTIANLRDKTKVLDLYGGQTADGTAIQVFNSNGGNNQIWNISNP*
>PROKKA_00016 HA 17 kDa subunit
MSAERTFLPNGNYNIKSIFSDSLYLNTVSKSLTFSNGSSANNQKWNVEYMAENRCFKISN
VAEPNKYLSYDNFGFISLDSLSNRCYWFPIKIAVNTYIMLSLNKVNDLDYAWDIYDTNEN
ILSQPLLLLPNFDIYNSNQMFKLEKI*
>PROKKA_00017 Hemagglutinin components HA-22/23/53 precursor
MNSSIKKIYNDIQEKVINYSDTIDLADGNYVVSRGDGWILSRQNQILGGSVISNGSTGIV
GDLRINDNAIPYYYPTPSFNEEYIKNNIQTVFANFTKANQIPIGFEFSKTAPSNKNLYMY
LQYTYIRYEIIKVLQHEIIERAVLYVPSLGYVKSIEFNPGEKINKDFYFLTNDKCILNEQ
FLYKKILETTKNIPTNNIFNSKVSSTQRVLPYSNGLYVINKGDGYIRTNDKDLIGTLLIE
AGSSGSIIQPRLRNTTRPLFTTSNDAKFSQQYTEERLKDAFNVQLFNTSTSLFKFVEEAP
SNKNICIKAYNTYEKYELIDYQNGSIVNKAEYYLPSLGYCEVTNAPSPESEVVKTQVAED
GFIQNGPEEEIVVGVIDPSENIQEINTAISDNYTYNIPGIVNNNPFYILFTVNTTGIYKI
NAQNNLPSLKIYEAIGSGNRNFQSGNLCDDDIKAINYITGFDSPNAKSYLVVLLNKDKNY
YIRVPQTSSNIENQIKFKREEGDLRNLMNSSVNIIDNLNSTGAHYYTRQSPDVHDYISYE
FTIPGNFNNKDTSNIRLYTSYNQGIGTLFRVTETIDGYNLINIQQNLNLLNSTKSIRLLN
GAIYILKVEVTELNNYNIKLHIDITN*
>PROKKA_00018 hypothetical protein
MCDKKYIIEFLIYLSIVILVIIISSEVCMYTFNFKQIIIRLI*
>PROKKA_00019 hypothetical protein
MKIKHPKVNEYYNYLKESFANVNLSEEHRMDIYKRIEIIEALVGLYEQKYEFDDEIIEDL
KLKYRPVFPEELKNIQKNLEKTIIK*
>PROKKA_00020 hypothetical protein
MDIPDIPEYLIETIFENIDQRLKQNFYNFYENLFNMNNKEENLKLLIKDIIQKEFMVAEL
TKISDMDLHKTKHTFIAPDKINKLKRYNLQQIKQTKKRWYNSLFKKKKTNPFNIEIETAN
NNITLYGPEVFFNLYKVRSIEELKDIRAAQFKDWLDNSIFITDFFYLKSKTNKQINTAFN
LDFIYNICTIIYDKWNNNLNFIYMEYPKLLLDHPLVADGSGKIKVHKQTIIQQNQSNKDV
KYKYNDYVSKDGITRILVPESNIDTKQSRLIDNKDLNILSNILKYKKADFLTNKTIVFNL
IDIINNIYCSKTVRSYEDLRNRIAKMTLLKFNFFRTDNTSGIPDAVYGIFSSYEYLDKSQ
NRVKVYVDSILYDKILKNQVYTIYNDKINQLNDDFAKTLVIYLQQEKLVLYTQGKNTTFL
SYDYFSNLVRFRYKKEERNYKIIAQALENMKCNNIIIRDFKKHMNGFIITFLDTNQFEIS
DLFSNKNTSDIIPMI*
>PROKKA_00021 hypothetical protein
MALAIEKLFFNVSKNLIHFITEPIPLYHYKTISFNKCCYCPFYKKMNDKNIHNYCSNYCN
NKYKKVIKKYNIYSNINIDKTHIQFSLTQIKQMLIYYYYANSKGLVSLISKKRIAKMIGC
CEKTVDINNKLFSDLGLILISGTINNKFSLIIKDYSEHYSKNNAGYLNLATNVFKDLLHI
NNVNALRIALQGILKHDINTILDRETYFSINSMKSFLPEYINCKSAIEKIICKLNSNTIT
MLFNSSEKLIFVISKNLHGKLLKKEMYYKYKNNFLNYITENNIKLNNLSHSINNIVKLSF
EYGYDIVQLMLGEIKDIAPTIFNVGGYIRDKIKRYIYMNEPFFAI*
>PROKKA_00022 hypothetical protein
MEILYYVNNETNSLLVTTEEKDHMHYIKTNKKDFLKYKKAGYAIITSAEMDFDLCLKMFS
PTFKEKIINIIKKAIQNEYIIAEKRTDNKYTISVIDSNFKLVL*
>PROKKA_00023 DNA-directed RNA polymerase subunit alpha
MRKNKRDELRELNLSIIAYNSLRNMGINTLEDLSMYSKKQLYQFKGIGIVSLRKIEKGLD
KKNMKMEAV*
